Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (791-800 of 932) with videos related to

Pageof 94
Sort By:
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
European Urology Oncology|January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium AnalysisMehul Gupta, Connor Wells, Meredith M Regan, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
Cancer Discovery|December 11, 2021
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and CancerArielle Elkrief, Julie T Wu, Chinmay Jani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Scientific Reports|February 9, 2020
Generation of light-producing somatic-transgenic mice using adeno-associated virus vectorsRajvinder Karda, Ahad A Rahim, Andrew M S Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without AbirateroneRana R McKay, Huihui Ye, Wanling Xie, et al.
Pageof 94

Showing results (791-800 of 932) with videos related to

Sort By:
Pageof 94
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
European Urology Oncology|January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium AnalysisMehul Gupta, Connor Wells, Meredith M Regan, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
Cancer Discovery|December 11, 2021
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and CancerArielle Elkrief, Julie T Wu, Chinmay Jani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Scientific Reports|February 9, 2020
Generation of light-producing somatic-transgenic mice using adeno-associated virus vectorsRajvinder Karda, Ahad A Rahim, Andrew M S Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without AbirateroneRana R McKay, Huihui Ye, Wanling Xie, et al.
Pageof 94